OA09144A - Improved interferon therapy. - Google Patents

Improved interferon therapy.

Info

Publication number
OA09144A
OA09144A OA59679A OA59679A OA09144A OA 09144 A OA09144 A OA 09144A OA 59679 A OA59679 A OA 59679A OA 59679 A OA59679 A OA 59679A OA 09144 A OA09144 A OA 09144A
Authority
OA
OAPI
Prior art keywords
interferon
interferon therapy
improved interferon
improved
hyperallergenicity
Prior art date
Application number
OA59679A
Other languages
English (en)
Inventor
M Cummins Joseph
Original Assignee
Amarillo Cell Culture Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25455330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA09144(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarillo Cell Culture Co filed Critical Amarillo Cell Culture Co
Publication of OA09144A publication Critical patent/OA09144A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA59679A 1986-11-06 1989-11-10 Improved interferon therapy. OA09144A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92783486A 1986-11-06 1986-11-06

Publications (1)

Publication Number Publication Date
OA09144A true OA09144A (en) 1991-10-31

Family

ID=25455330

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59679A OA09144A (en) 1986-11-06 1989-11-10 Improved interferon therapy.

Country Status (10)

Country Link
US (1) US5019382A (de)
EP (1) EP0341258B1 (de)
KR (1) KR960003377B1 (de)
AT (1) ATE102047T1 (de)
AU (1) AU2634592A (de)
DE (1) DE3789239T2 (de)
HK (1) HK24695A (de)
OA (1) OA09144A (de)
WO (1) WO1988003411A1 (de)
ZA (1) ZA878295B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5298222A (en) * 1989-08-09 1994-03-29 Osteotech, Inc. Process for disinfecting musculoskeletal tissue and tissues prepared thereby
FR2654343B1 (fr) * 1989-11-10 1994-08-05 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
EP0578823B1 (de) * 1991-04-08 2002-01-23 Sumitomo Pharmaceuticals Company, Limited Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
JPH07501320A (ja) * 1991-10-11 1995-02-09 ギリーズ，マーク・セドリック インタ−フェロン・アルファによる眼線維症の治療
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0619120B1 (de) * 1993-04-09 2002-09-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
US7790153B2 (en) * 1994-04-12 2010-09-07 Research Development Foundation Method of treating rheumatoid arthritis using orally administered type one interferons
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
EP0790062B1 (de) * 1995-08-30 2006-05-10 Toray Industries, Inc. Verfahren zum testen von myocarditis und cardiomyopathie
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
AU722987B2 (en) * 1996-02-28 2000-08-17 Unihart Corporation Pharmaceutical compositions comprising natural human alpha-interferon
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
WO1997039762A1 (en) * 1996-04-22 1997-10-30 Rothschild, Peter, R. Stabilized antihepatitis-b vaccine tablets
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
NZ332689A (en) 1996-05-09 2000-07-28 Pharma Pacific Pty Ltd Using interferon to treat autoimmune, mycobacterial or neurodegenerative disease
DK0920329T3 (da) * 1996-05-09 2003-01-27 Feronpatent Ltd Stabilisering af interferoner i vandig opløsning med gummiarabicum
US20030108519A1 (en) * 1996-05-09 2003-06-12 Pharma Pacific Pty Ltd. Therapeutic applications of high dose in terferon
AU730020B2 (en) * 1997-05-09 2001-02-22 Feronpatent Limited Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
FI980216A0 (fi) * 1998-01-30 1998-01-30 Bene Pharma Oy Medicin foer behandling av vaorfor
CN1108815C (zh) * 1998-02-25 2003-05-21 上海华晨生物技术研究所 复方α干扰素含片及其制备方法
US6036949A (en) * 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
JP2003516360A (ja) * 1999-12-09 2003-05-13 カイロン コーポレイション 中枢神経系およびリンパ系に対するサイトカイン投与方法
WO2001072312A1 (en) * 1999-12-22 2001-10-04 Viron Corporation Antiviral therapeutic composition and treatment
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US20020197235A1 (en) 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
WO2003016472A2 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
US20050013801A1 (en) * 2001-10-05 2005-01-20 Hsu Henry H. Methods of treating liver fibrosis and hepatitis c virus infection
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
JP2006501137A (ja) * 2002-01-16 2006-01-12 ペプジェン コーポレイション インターフェロン−τの経口投与
US7625554B2 (en) * 2002-09-05 2009-12-01 Brod Staley A Treatment of alzheimer's disease
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
BR0314548A (pt) * 2002-09-27 2005-08-09 Biogen Idec Inc Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2005179268A (ja) * 2003-12-19 2005-07-07 Gc Corp 口腔用組成物
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
US20050276785A1 (en) * 2004-06-09 2005-12-15 Schering Aktiengesellschaft Treatment of cardiomyopathy and of endothelial dysfunction
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DK1985303T3 (da) 2006-01-12 2013-02-25 Kitasato Daiichi Sankyo Vaccine Co Ltd Oral sammensætning indeholdende interferon-alpha
US8075877B2 (en) * 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
CA2644670A1 (en) * 2006-03-08 2008-05-08 Hemispherx Biopharma Inc. Broad spectrum immune and antiviral gene modulation by oral interferon
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8936782B2 (en) * 2011-11-22 2015-01-20 Cedars-Sinai Medical Center Interferon beta as antibacterial agents
US9642893B2 (en) 2013-07-03 2017-05-09 Joseph Cummins Method for reducing injury and stabilizing muscle using orally administered interferon
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
RU2690677C1 (ru) 2018-06-27 2019-06-05 Георгий Георгиевич Чумбуридзе Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE180737C (de) *
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
ZA754725B (en) * 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DK485977A (da) * 1977-11-01 1979-05-02 Ess Foodeksport Fremgangsmaade til udvinding af et biologisk aktivt materiale fra svineblodfraktioner
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4713239A (en) * 1979-05-29 1987-12-15 Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr Antianginal film and method of treating ischemic heart disease
US4358376A (en) * 1979-10-29 1982-11-09 Terumo Corporation Apparatus for detoxifying body fluid
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
EP0058192A1 (de) * 1980-08-22 1982-08-25 University of Illinois Foundation Abgabe biologisch aktiver komponenten aus interferon isolierten der heterologischen species
EP0090837A1 (de) * 1981-10-08 1983-10-12 BERG, Kurt Frimann Verfahren und zusammensetzung zum behandeln von kranken die an interferon empfindlichen krankheiten leiden
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
ATE52693T1 (de) * 1982-10-25 1990-06-15 Genentech Inc Synergistische humaninterferonaktivitaet.
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4699136A (en) * 1983-12-22 1987-10-13 Krauser Robert S Method and apparatus for treating ailments
US4649075A (en) * 1984-08-09 1987-03-10 Leonora Jost Transdermal and transmucosal vortexed foam devices and the method of making
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0177342A3 (de) * 1984-10-04 1987-12-02 Genentech, Inc. Orale Formulierungen therapeutischer Proteine
US4710191A (en) * 1985-12-16 1987-12-01 Jonergin, Inc. Therapeutic device for the administration of medicaments
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation

Also Published As

Publication number Publication date
EP0341258B1 (de) 1994-03-02
AU2634592A (en) 1992-12-03
KR960003377B1 (ko) 1996-03-09
DE3789239T2 (de) 1994-06-16
ZA878295B (en) 1988-05-03
WO1988003411A1 (en) 1988-05-19
KR890700035A (ko) 1989-03-02
AU1222788A (en) 1988-06-01
ATE102047T1 (de) 1994-03-15
EP0341258A1 (de) 1989-11-15
AU625431B2 (en) 1992-07-09
US5019382A (en) 1991-05-28
HK24695A (en) 1995-03-03
EP0341258A4 (en) 1990-10-10
DE3789239D1 (de) 1994-04-07

Similar Documents

Publication Publication Date Title
ZA878295B (en) Treatment of immuno-resistant disease
KR100321467B1 (de)
DE3583849D1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
DE69003392D1 (de) Dosisform zur oralen verabreichung des hypoglykämischen glipizids.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ATE149362T1 (de) Vorrichtung zum verabreichen von medikamenten auf schleimhautgewebe
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
ATE67677T1 (de) Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten.
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
EG17992A (en) Preparation of a medicament for arthritis and theumatism
DK374388A (da) Immunterapeutisk, oral interferondosisform samt fremgangsmaade til fremstilling heraf
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
DE3689254D1 (de) Arzneimittel auf Dextrorphanbasis zur intranasalen Applikation.
DE3686536D1 (de) Oxytocin und antigestagen zur einleitung der geburt.
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
MY102687A (en) Novel galenical comprising a somatostatin formulations.
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
RU2000117991A (ru) Способ лечения затяжных, рецидивирующих форм псевдотуберкулеза и его специфических осложнений у детей
MD1469G2 (ro) Metodă de tratament al şocului combustional